Trial Outcomes & Findings for Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR) (NCT NCT02571673)
NCT ID: NCT02571673
Last Updated: 2024-04-15
Results Overview
Using data from survivors in Aim 1: Part 2 (N=45), we will abstract data on health care actions from both the medical record and HN-STAR. Such data include receipt of appropriate oncologic surveillance, identification and management of symptoms, and appropriate preventive health services, as indicated by referrals, prescriptions, and recommendations in both clinic notes and the HN-STAR Survivor Self-Assessment. For each participant, HN-STAR generates a Treatment Summary/TS for the clinician to review and verify its accuracy compared with clinical documentation with the participant medical record.
COMPLETED
65 participants
2 years
2024-04-15
Participant Flow
Participant milestones
| Measure |
Survivors of Head and Neck Cancer
Participants must have completed treatment for head and neck cancer at least 1 year prior to survivorship visit and have no evidence of disease.
|
|---|---|
|
Overall Study
STARTED
|
65
|
|
Overall Study
COMPLETED
|
65
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)
Baseline characteristics by cohort
| Measure |
Survivors of Head and Neck Cancer
n=65 Participants
Participants must have completed treatment for head and neck cancer at least 1 year prior to survivorship visit and have no evidence of disease.
|
|---|---|
|
Age, Continuous
|
60 years
n=99 Participants
|
|
Sex: Female, Male
Female
|
13 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
52 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
65 Participants
n=99 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=99 Participants
|
|
Race (NIH/OMB)
White
|
57 Participants
n=99 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
4 Participants
n=99 Participants
|
|
Region of Enrollment
United States
|
65 Participants
n=99 Participants
|
PRIMARY outcome
Timeframe: 2 yearsUsing data from survivors in Aim 1: Part 2 (N=45), we will abstract data on health care actions from both the medical record and HN-STAR. Such data include receipt of appropriate oncologic surveillance, identification and management of symptoms, and appropriate preventive health services, as indicated by referrals, prescriptions, and recommendations in both clinic notes and the HN-STAR Survivor Self-Assessment. For each participant, HN-STAR generates a Treatment Summary/TS for the clinician to review and verify its accuracy compared with clinical documentation with the participant medical record.
Outcome measures
| Measure |
Survivors of Head and Neck Cancer
n=45 Participants
Participants must have completed treatment for head and neck cancer at least 1 year prior to survivorship visit and have no evidence of disease.
|
|---|---|
|
Recommendations for Cancer Surveillance (Patient-reported Outcomes From the Survivor Self-Assessment)
|
93 % of pts w/accurate TS for primary site
|
Adverse Events
Survivors of Head and Neck Cancer
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Talya Salz, PhD
Memorial Sloan Kettering Cancer Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place